<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Somapacitan: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Somapacitan: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Somapacitan: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="129445" href="/d/html/129445.html" rel="external">see "Somapacitan: Drug information"</a> and <a class="drug drug_patient" data-topicid="129477" href="/d/html/129477.html" rel="external">see "Somapacitan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58231541"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sogroya</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F59025054"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Sogroya</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F58569832"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Growth Hormone</span></li></ul></div>
<div class="block dop drugH1Div" id="F58555872"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Somapacitan is available in multiple strengths of prefilled pens; use caution when prescribing and administering. Fundoscopic exam should be performed prior to initiation. Use actual body weight for dosing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86c2efe3-e9ce-40fa-a8a2-57d2259272bd">Growth hormone deficiency, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Growth hormone deficiency, treatment:</b> Children ≥2.5 years and Adolescents: SUBQ: Initial dose: 0.16 mg/kg/dose once weekly; individualize and titrate dose based on patient response. If epiphyses are closed, reevaluate patient before continuing therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Converting from daily growth hormone products</i>: Begin therapy 1 day after last daily injection of other product.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Malignancy:</b> Discontinue therapy if evidence of tumor progression/recurrence of preexisting malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Papilledema:</b> Discontinue therapy if papilledema occurs; if papilledema is a result of intracranial hypertension, may consider restarting at a lower dose once signs/symptoms of intracranial hypertension resolve.</p></div>
<div class="block dorp drugH1Div" id="F58555873"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; drug exposure increases with decreasing eGFR.</p></div>
<div class="block dohp drugH1Div" id="F58555874"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2.5 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: There are no dosage adjustments necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment: Use is not recommended (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F54896958"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="129445" href="/d/html/129445.html" rel="external">see "Somapacitan: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e8b2a76-a8e6-4141-90b5-bdcc17fc4670">Growth hormone deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Growth hormone deficiency: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SubQ:</b> Initial: 1.5 mg once weekly; may increase dose by 0.5 to 1.5 mg/week every 2 to 4 weeks based on clinical response and insulin-like growth factor 1 (IGF-1) levels; reduce dose if needed for adverse reactions or elevated IGF-1 levels. Maximum dose: 8 mg/week.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Duration of therapy:</i> Consider discontinuing therapy if no apparent benefits are achieved after 12 to 18 months; therapy may be continued indefinitely if benefits are achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31760824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31760824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Missed doses: </i>Administer missed dose as soon as possible within 3 days; resume usual schedule thereafter. If &gt;3 days have passed since the missed dose, skip dose and administer next dose on the next regular dosing day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F54896960"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; drug exposure increases with decreasing eGFR.</p></div>
<div class="block doha drugH1Div" id="F54896961"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment: Initial: 1 mg once weekly; adjust dose in smaller increments (maximum dose: 4 mg/week).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is not recommended (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55714704"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Fluid retention</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fluid retention may occur with growth hormone (GH) therapy; effects are generally transient and dose dependent. Manifestations of fluid retention may include <b>peripheral edema</b>, <b>arthralgia,</b> myalgia, and nerve compression syndromes (including carpal tunnel syndrome or paresthesias).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent; exact mechanism is unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10592455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10592455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; onset of symptoms consistent with fluid retention generally occur within 1 to 3 months of initiation or dose increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9196611','lexi-content-ref-7554308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9196611','lexi-content-ref-7554308'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients being treated for adult-onset GH deficiency, especially those with an increased body mass index (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9196611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9196611'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Glucose tolerance</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Treatment with growth hormone (GH) products, including somapacitan, may decrease insulin sensitivity. Previously undiagnosed impaired glucose tolerance or diabetes mellitus may be detected; new-onset type 2 diabetes mellitus and exacerbation of preexisting diabetes mellitus may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent; related to the pharmacologic action. Somapacitan is a human GH analog which may antagonize the hepatic and peripheral effects of insulin on glucose metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19240267','lexi-content-ref-27736009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19240267','lexi-content-ref-27736009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; in one long-term observational trial of adults with GH deficiency receiving GH therapy, new diagnosis of type 2 diabetes occurred between 9 and 29 months of GH therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27736009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27736009'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting type 1 or 2 diabetes mellitus, prediabetes, risk factors for developing diabetes mellitus (eg, obesity, family history)</p>
<p style="text-indent:-2em;margin-left:6em;">• Turner syndrome</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Intracranial hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Intracranial hypertension (IH) with headache, nausea, papilledema, visual changes, and/or vomiting has been reported in patients treated with growth hormone products (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31741184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31741184'])">Ref</a></span>); signs and symptoms of IH may rapidly resolve after discontinuation or reduction of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Exact mechanism is unknown; may be dose related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7776116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7776116'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; according to the manufacturer, symptoms usually occur within the first 8 weeks of therapy. IH has also appeared after several years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16496267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16496267'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting IH (eg, preexisting papilledema)</p>
<p style="text-indent:-2em;margin-left:6em;">• In general, idiopathic intracranial hypertension is most commonly reported in females of childbearing age and with a high body mass index (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31741184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31741184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic kidney insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11086659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11086659'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neoplasm</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Growth hormone (GH) therapy may increase the risk of malignancy progression in patients with active malignancy. Malignant transformation or growth of preexisting nevi may also occur. An increased risk of second neoplasms, primarily meningiomas, has also been reported in pediatric patients who developed GH deficiency (GHD) after receiving radiation to the head/brain for first neoplasm. The use of GH therapy in GH-deficient patients without other risk factors for malignancy does not appear to increase the risk of developing malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30500870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30500870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of preexisting malignancy, especially active malignancies or patients with malignancies who have not yet completed treatment.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>The American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) guidelines for the management of GH deficiency in adults suggest waiting ≥5 years after cancer remission before initiating low-dose recombinant human GH therapy due to the increased risk of secondary neoplasm (particularly adult survivors of childhood cancers); specific data on the effects of recombinant GH replacement and cancer risk are lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31760824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31760824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of preexisting nevi</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients treated for GHD after radiation to head/brain for first neoplasm (risk for second neoplasm [eg, meningioma])</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Slipped capital femoral epiphyses</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients receiving growth hormone (GH) therapy can develop slipped capital femoral epiphyses (SCFE) at an incidence rate higher than the general population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706','lexi-content-ref-27884013','lexi-content-ref-28671425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706','lexi-content-ref-27884013','lexi-content-ref-28671425'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Exact mechanism is unknown; recombinant GH may reduce resistance to shear stresses and contributes to the widening of the weakest zone of the epiphyseal plate enhancing weakness of the growth plate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706','lexi-content-ref-27884013','lexi-content-ref-28671425']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706','lexi-content-ref-27884013','lexi-content-ref-28671425'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; the median onset from the start of GH therapy ranges from 0.4 to 2.5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706','lexi-content-ref-27884013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706','lexi-content-ref-27884013'])">Ref</a></span>) though there seems to be no correlation between the occurrence of SCFE and duration of GH therapy (Darendeliler 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i>
<i></i></p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid growth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706','lexi-content-ref-27884013','lexi-content-ref-23818448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706','lexi-content-ref-27884013','lexi-content-ref-23818448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior cancer diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23818448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23818448'])">Ref</a></span>), including craniopharyngioma and cranial tumor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Total body irradiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706','lexi-content-ref-23818448','lexi-content-ref-17493896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706','lexi-content-ref-23818448','lexi-content-ref-17493896'])">Ref</a></span>) or radiation exposure to the spinal area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11086659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11086659'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706','lexi-content-ref-23818448','lexi-content-ref-17493896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706','lexi-content-ref-23818448','lexi-content-ref-17493896'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706','lexi-content-ref-23818448','lexi-content-ref-17493896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706','lexi-content-ref-23818448','lexi-content-ref-17493896'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Turner syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Panhypopituitarism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18174706']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18174706'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54816171"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum phosphate (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (children: 12%; no neutralizing antibodies were detected)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (3%), peripheral edema (3%)<span class="lexi-table-link-container"> (<a aria-label="Somapacitan: Adverse Reaction: Peripheral Edema table link" class="lexi-table-link" data-table-id="lexi-content-somapacitan-adverse-reaction-peripheral-edema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-somapacitan-adverse-reaction-peripheral-edema')">table 1</a>)</span><span class="table-link" style="display:none;">Somapacitan: Adverse Reaction: Peripheral Edema</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Somapacitan: Adverse Reaction: Peripheral Edema" frame="border" id="lexi-content-somapacitan-adverse-reaction-peripheral-edema" rules="all">
<caption style="text-align:center;">
<b>Somapacitan: Adverse Reaction: Peripheral Edema</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Somapacitan)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Somapacitan)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">61</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (3%), weight gain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (5%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (4%), sleep disorder (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (7%)<span class="lexi-table-link-container"> (<a aria-label="Somapacitan: Adverse Reaction: Arthralgia table link" class="lexi-table-link" data-table-id="lexi-content-somapacitan-adverse-reaction-arthralgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-somapacitan-adverse-reaction-arthralgia')">table 2</a>)</span><span class="table-link" style="display:none;">Somapacitan: Adverse Reaction: Arthralgia</span>, back pain (10%), increased creatine phosphokinase in blood specimen (3% to 9%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Somapacitan: Adverse Reaction: Arthralgia" frame="border" id="lexi-content-somapacitan-adverse-reaction-arthralgia" rules="all">
<caption style="text-align:center;">
<b>Somapacitan: Adverse Reaction: Arthralgia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Somapacitan)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Somapacitan)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">61</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Tonsillitis (3%)</p></div>
<div class="block coi drugH1Div" id="F54801917"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to somapacitan or any component of the formulation; acute critical illness after open heart surgery, abdominal surgery, or multiple accidental trauma; acute respiratory failure; active malignancy; active proliferative or severe nonproliferative diabetic retinopathy; pediatric patients with closed epiphyses; Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment.</p></div>
<div class="block war drugH1Div" id="F54896939"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Has been rarely reported in pediatric patients receiving somatropin; incidence in children may be greater than adults. Consider pancreatitis diagnosis if abdominal pain occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute critical illness: Somapacitan is contraindicated in patients with acute critical illness due to potential complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure; these concerns are based on studies that showed increased mortality in critically ill patients without growth hormone deficiency who were receiving supraphysiologic doses of growth hormone. Safety of continuing growth hormone products used at lower doses (eg, for replacement therapy) has not been established during critical illness.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in patients with severe hepatic impairment; dosage adjustment is required in patients with moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoadrenalism: Patients who have or are at risk for pituitary hormone deficiency(ies) may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism with somapacitan therapy; patients with previously diagnosed hypoadrenalism may require increased dosages of glucocorticoids due to the effects of somapacitan.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: Patients who have or are at risk for pituitary hormone deficiency(ies) may be at risk for reduced thyroid function (central hypothyroidism). Untreated/undiagnosed hypothyroidism may decrease response to therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prader-Willi syndrome: Sudden death has been reported in pediatric patients with Prader-Willi syndrome following the use of somatropin. The reported fatalities occurred in patients with ≥1 risk factor, including severe obesity, history of upper airway obstruction or sleep apnea, respiratory impairment, or unidentified respiratory infection; male patients may be at greater risk. Use of somapacitan is not indicated for the treatment of pediatric patients who have growth failure due to Prader-Willi syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Scoliosis: Progression of scoliosis may occur in pediatric patients experiencing rapid growth.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age may be more sensitive to the actions of somapacitan due to greater drug exposure than patients &lt;65 years of age at the same dose level; lower starting doses and smaller dose increments are required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Failure to increase growth rate, particularly during the first year of therapy, indicates need for close assessment of compliance and evaluation for other causes of growth failure, such as hypothyroidism, undernutrition, advanced bone age, and antibodies to recombinant human growth hormone.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Multiple-dose injection pens: According to the Centers for Disease Control and Prevention, pen-shaped injection devices should never be used for more than 1 person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p></div>
<div class="block foc drugH1Div" id="F58231542"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sogroya: Somapacitan-beco 5 mg/1.5 mL (1.5 mL); Somapacitan-beco 10 mg/1.5 mL (1.5 mL); Somapacitan-beco 15 mg/1.5 mL (1.5 mL) [contains phenol]</p></div>
<div class="block geq drugH1Div" id="F58231540"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58262601"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Pen-injector</b> (Sogroya Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/1.5 mL (per mL): $1,116.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/1.5 mL (per mL): $2,233.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/1.5 mL (per mL): $3,349.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F59025055"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Pen-injector, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sogroya: Somapacitan-beco 5 mg/1.5 mL (1.5 mL); Somapacitan-beco 10 mg/1.5 mL (1.5 mL); Somapacitan-beco 15 mg/1.5 mL (1.5 mL) [contains phenol]</p></div>
<div class="block admp drugH1Div" id="F58555888"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: SUBQ: For SUBQ administration only. Administer into the upper arm, thigh, abdomen, or buttocks. Administer on the same day each week; rotate injection site weekly. Solution should be clear to slightly opalescent and colorless to slightly yellow; do not use if solution is cloudy or contains particles. Prior to first use, each new pen must be primed; see manufacturer's labeling for specific priming procedure and additional administration instructions. Attach a new disposable needle to pen for each dose; set dial to appropriate dose, insert needle into clean skin, and activate device by holding the button down; continue to hold the button until the dose window reads "0." After the dose returns to "0," continue to hold the needle in the skin for ~6 seconds before removing the needle to ensure the full dose has been administered. Dispose of used needle. Doses delivered and increments vary with pen strength; verify correct pen is utilized.</p>
<p style="text-indent:-2em;margin-left:4em;">5 mg/1.5 mL prefilled pen: Device delivers doses from 0.025 to 2 mg in 0.025 mg increments; prime pen with 0.025 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">10 mg/1.5 mL prefilled pen: Device delivers doses from 0.05 to 4 mg in 0.05 mg increments; prime pen with 0.05 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">15 mg/1.5 mL prefilled pen: Device delivers doses from 0.1 to 8 mg in 0.1 mg increments; prime pen with 0.1 mg.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses: </i>Administer a missed dose as soon as possible if it is ≤3 days after the scheduled dose; resume usual schedule thereafter. If &gt;3 days have passed since the missed dose, skip dose and administer next dose on the next regular dosing day.</p></div>
<div class="block adm drugH1Div" id="F54896962"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> For SUBQ administration into the abdomen, buttocks, thigh, or upper arm. Rotate injection site weekly to avoid lipohypertrophy. Solution should be clear to slightly opalescent and colorless to slightly yellow; do not use if solution is cloudy or contains particles. Prime unused pen devices before injecting. Once injected, keep the needle in the skin for ~6 seconds after the dose dial has returned to 0 mg before removing the needle to ensure the full dose has been administered. Prefilled pen devices deliver doses from 0.025 to 2 mg in increments of 0.025 mg (5 mg/1.5 mL) or 0.05 to 4 mg in increments of 0.05 mg (10 mg/1.5 mL) or 0.1 to 8 mg in increments of 0.1 mg (15 mg/1.5 mL). Refer to manufacturer’s labeling for product-specific details.</p></div>
<div class="block sts drugH1Div" id="F54896944"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store unopened prefilled pen in a refrigerator at 2°C to 8°C (36°F to 46°F) with the cap on and in the original carton to protect from light. After opening, store in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 6 weeks. Prefilled pen (opened or unopened) may be temporarily exposed to room temperature up to 25°C (77°F) for a total of 72 hours. Do not freeze. Discard prefilled pen if it has been frozen or kept &gt;30°C (86°F). Avoid exposing pen to direct or excessive heat or sunlight.</p></div>
<div class="block usep drugH1Div" id="F58555853"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of growth failure due to inadequate endogenous growth hormone secretion (FDA approved in pediatric patients ages ≥2.5 years); replacement of endogenous growth hormone in adults with growth hormone deficiency (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F54896935"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Somapacitan may be confused with homatropine, Soma, somatropin, sumatriptan.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Growth hormone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older except as hormone replacement in patients with growth hormone deficiency due to an established etiology that is based on a rigorous diagnosis by evidence-based criteria due to its minimal impact on body composition and its association with causing edema, arthralgia, carpal tunnel syndrome, gynecomastia, and impaired fasting glucose (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54846709"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54846706"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cortisone: May diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Cortisone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Growth Hormone Analogs. Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Products that Affect Growth Hormone may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: May diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of PredniSONE.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54896937"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Growth hormone replacement therapy may improve amenorrhea, dysmenorrhea, and fertility in females with growth hormone deficiency (information not specific to use of somapacitan) (Vila 2018).</p></div>
<div class="block pri drugH1Div" id="F54896936"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">During normal pregnancy, maternal production of endogenous growth hormone decreases as placental growth hormone production increases. Continued use of short-acting growth hormone replacement early in pregnancy in patients with growth hormone deficiency has not been associated with adverse pregnancy outcomes (information not specific to use of somapacitan) (Vila 2018).</p></div>
<div class="block mopp drugH1Div" id="F58555889"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Growth response; weight; serum insulin-like growth factor-1 (IGF-1); funduscopic exam prior to treatment; progression of scoliosis in patients with a history of scoliosis; clinical evidence of slipped capital femoral epiphysis (such as a limp or hip or knee pain); thyroid function; glucose in patients with risk factors for glucose intolerance; cortisol in patients with known hypoadrenalism; progression or recurrence of tumor in patients treated for growth deficiency secondary to a tumor or tumor development in at-risk patients; progression of preexisting nevi. In addition, guidelines recommend a physical exam at every visit; adrenal and thyroid function in patients with growth hormone deficiency due to multiple pituitary hormone deficiencies; funduscopic exam if symptoms of intracranial hypertension occur (PES [Grimberg 2016]).</p></div>
<div class="block pha drugH1Div" id="F54896945"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Somapacitan is a human growth hormone analog of recombinant DNA origin with a single substitution in the amino acid backbone to which an albumin-binding moiety has been attached. Somapacitan binds to a dimeric growth hormone receptor in the cell membrane of target cells resulting in multiple pharmacodynamic effects; some of these effects are primarily mediated by insulin-like growth factor 1 produced in the liver, while others are primarily a consequence of the direct effects of somapacitan.</p></div>
<div class="block phk drugH1Div" id="F54896946"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: ≥7 days (Rasmussen 2014; Rasmussen 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients: 1.7 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~14.6 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive; via proteolytic cleavage of the linker sequence between the peptide backbone and albumin binder sidechain.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~2 to 3 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Single dose: 4 to 24 hours (dose dependent); steady state is achieved after 1 to 2 weeks of once weekly SubQ administration (Rasmussen 2014; Rasmussen 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: ~81%; feces: ~13%.</p></div>
<div class="block phksp drugH1Div" id="F54896954"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Drug exposure increases with decreasing eGFR (AUC increased by 1.75-fold in severe renal impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function: C<sub>max</sub> was 3.52-fold higher in patients with moderate hepatic impairment compared to patients with normal hepatic function.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Patients ≥65 years of age have greater drug exposure than patients &lt;65 years of age at the same dose level.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30500870">
<a name="30500870"></a>Boguszewski CL, Boguszewski MCDS. Growth hormone's links to cancer. <i>Endocr Rev</i>. 2019;40(2):558-574. doi:10.1210/er.2018-00166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/30500870/pubmed" id="30500870" target="_blank">30500870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. <a href="https://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html" target="_blank">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 4, 2012. Accessed September 14, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9196611">
<a name="9196611"></a>Chipman JJ, Attanasio AF, Birkett MA, Bates PC, Webb S, Lamberts SW. The safety profile of GH replacement therapy in adults. <i>Clin Endocrinol (Oxf)</i>. 1997;46(4):473-481. doi:10.1046/j.1365-2265.1997.1660984.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/9196611/pubmed" id="9196611" target="_blank">9196611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18174706">
<a name="18174706"></a>Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. <i>Horm Res</i>. 2007;68(Suppl 5):41-47. doi:10.1159/000110474<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/18174706/pubmed" id="18174706" target="_blank">18174706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736313">
<a name="27736313"></a>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab.</i> 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/27736313/pubmed" id="27736313" target="_blank">27736313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27884013">
<a name="27884013"></a>Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulin-like growth factor-i treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. <i>Horm Res Paediatr</i>. 2016;86(6):361-397. doi:10.1159/000452150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/27884013/pubmed" id="27884013" target="_blank">27884013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7554308">
<a name="7554308"></a>Holmes SJ, Shalet SM. Which adults develop side-effects of growth hormone replacement? <i>Clin Endocrinol (Oxf)</i>. 1995;43(2):143-149. doi: 10.1111/j.1365-2265.1995.tb01908.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/7554308/pubmed" id="7554308" target="_blank">7554308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7776116">
<a name="7776116"></a>Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. <i>J Pediatr</i>. 1995;126(6):996-999. doi:10.1016/s0022-3476(95)70232-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/7776116/pubmed" id="7776116" target="_blank">7776116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11086659">
<a name="11086659"></a>Maneatis T, Baptista J, Connelly K, Blethen S. Growth hormone safety update from the National Cooperative Growth Study. <i>J Pediatr Endocrinol Metab</i>. 2000;13(suppl 2):1035-1044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/11086659/pubmed" id="11086659" target="_blank">11086659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21602453">
<a name="21602453"></a>Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society (ES). Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab.</i> 2011;96(6):1587-1609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/21602453/pubmed" id="21602453" target="_blank">21602453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10592455">
<a name="10592455"></a>Møller J, Nielsen S, Hansen TK. Growth hormone and fluid retention. <i>Horm Res</i>. 1999;51 Suppl 3:116-120. doi:10.1159/000053173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/10592455/pubmed" id="10592455" target="_blank">10592455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19240267">
<a name="19240267"></a>Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. <i>Endocr Rev</i>. 2009;30(2):152-177. doi:10.1210/er.2008-0027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/19240267/pubmed" id="19240267" target="_blank">19240267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23818448">
<a name="23818448"></a>Mostoufi-Moab S, Isaacoff EJ, Spiegel D, et al. Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy. <i>Pediatr Blood Cancer</i>. 2013;60(11):1766-1771. doi:10.1002/pbc.24667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/23818448/pubmed" id="23818448" target="_blank">23818448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28671425">
<a name="28671425"></a>Peck DM, Voss LM, Voss TT. Slipped capital femoral epiphysis: diagnosis and management. <i>Am Fam Physician</i>. 2017;95(12):779-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/28671425/pubmed" id="28671425" target="_blank">28671425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26727076">
<a name="26727076"></a>Rasmussen MH, Janukonyté J, Klose M, et al. Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency. <i>J Clin Endocrinol Metab</i>. 2016;101(3):988-998. doi:10.1210/jc.2015-1991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/26727076/pubmed" id="26727076" target="_blank">26727076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25013997">
<a name="25013997"></a>Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile. <i>J Clin Endocrinol Metab</i>. 2014;99(10):E1819-1829. doi:10.1210/jc.2014-1702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/25013997/pubmed" id="25013997" target="_blank">25013997</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sogroya (somapacitan-beco) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: A systematic review and critical assessment of drug-induced causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163-172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29521487">
<a name="29521487"></a>Vila G, Luger A. Growth hormone deficiency and pregnancy: any role for substitution? <i>Minerva Endocrinol</i>. 2018;43(4):451-457. doi:10.23736/S0391-1977.18.02834-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/29521487/pubmed" id="29521487" target="_blank">29521487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16496267">
<a name="16496267"></a>Vischi A, Guerriero S, Giancipoli G, Lorusso V, Sborgia G. Delayed onset of pseudotumor cerebri syndrome 7 years after starting human recombinant growth hormone treatment. <i>Eur J Ophthalmol</i>. 2006;16(1):178-180. doi:10.1177/112067210601600131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/16496267/pubmed" id="16496267" target="_blank">16496267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17493896">
<a name="17493896"></a>Wang SY, Tung YC, Tsai WY, Chien YH, Lee JS, Hwu WL. Slipped capital femoral epiphysis as a complication of growth hormone therapy. <i>J Formos Med Assoc</i>. 2007;106(2 Suppl):S46-S50. doi:10.1016/s0929-6646(09)60352-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/17493896/pubmed" id="17493896" target="_blank">17493896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736009">
<a name="27736009"></a>Weber MM, Biller BM, Pedersen BT, Pournara E, Christiansen JS, Höybye C. The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the <i>NordiNet</i> International Outcome Study. <i>Clin Endocrinol (Oxf)</i>. 2017;86(2):192-198. doi:10.1111/cen.13256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/27736009/pubmed" id="27736009" target="_blank">27736009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31760824">
<a name="31760824"></a>Yuen KCJ, Biller BMK, Radovick S, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. <i>Endocr Pract.</i> 2019;25(11):1191-1232. doi:10.4158/GL-2019-0405<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/somapacitan-pediatric-drug-information/abstract-text/31760824/pubmed" id="31760824" target="_blank">31760824</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 142477 Version 6.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
